280 related articles for article (PubMed ID: 30468800)
1. A combination of GATA3 and SOX10 is useful for the diagnosis of metastatic triple-negative breast cancer.
Tozbikian GH; Zynger DL
Hum Pathol; 2019 Mar; 85():221-227. PubMed ID: 30468800
[TBL] [Abstract][Full Text] [Related]
2. SOX10, GATA3, GCDFP15, Androgen Receptor, and Mammaglobin for the Differential Diagnosis Between Triple-negative Breast Cancer and TTF1-negative Lung Adenocarcinoma.
Laurent E; Begueret H; Bonhomme B; Veillon R; Thumerel M; Velasco V; Brouste V; Hoppe S; Fournier M; Grellety T; MacGrogan G
Am J Surg Pathol; 2019 Mar; 43(3):293-302. PubMed ID: 30628926
[TBL] [Abstract][Full Text] [Related]
3. GATA3 expression in breast carcinoma: utility in triple-negative, sarcomatoid, and metastatic carcinomas.
Cimino-Mathews A; Subhawong AP; Illei PB; Sharma R; Halushka MK; Vang R; Fetting JH; Park BH; Argani P
Hum Pathol; 2013 Jul; 44(7):1341-9. PubMed ID: 23375642
[TBL] [Abstract][Full Text] [Related]
4. Sry-related high-mobility-group/HMG box 10 (SOX10) as a sensitive marker for triple-negative breast cancer.
Jamidi SK; Hu J; Aphivatanasiri C; Tsang JY; Poon IK; Li JJ; Chan SK; Cheung SY; Tse GM
Histopathology; 2020 Dec; 77(6):936-948. PubMed ID: 32304249
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic utility and sensitivities of GATA3 antibodies in triple-negative breast cancer.
Krings G; Nystrom M; Mehdi I; Vohra P; Chen YY
Hum Pathol; 2014 Nov; 45(11):2225-32. PubMed ID: 25150746
[TBL] [Abstract][Full Text] [Related]
6. Combination of GATA3, SOX-10, and PAX8 in a Comprehensive Panel to Diagnose Breast Cancer Metastases.
Na K; Woo HY; DO SI; Kim SW
In Vivo; 2022; 36(1):473-481. PubMed ID: 34972751
[TBL] [Abstract][Full Text] [Related]
7. Combined use of SOX10 and GATA3 in mammary carcinoma.
Qazi MS; McGregor SM
Pathol Res Pract; 2020 Feb; 216(2):152801. PubMed ID: 31924335
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological, immunohistochemical and molecular correlation of neural crest transcription factor SOX10 expression in triple-negative breast carcinoma.
Harbhajanka A; Chahar S; Miskimen K; Silverman P; Harris L; Williams N; Varadan V; Gilmore H
Hum Pathol; 2018 Oct; 80():163-169. PubMed ID: 29894722
[TBL] [Abstract][Full Text] [Related]
9. Young investigator challenge: The utility of GATA3 immunohistochemistry in the evaluation of metastatic breast carcinomas in malignant effusions.
Lew M; Pang JC; Jing X; Fields KL; Roh MH
Cancer Cytopathol; 2015 Oct; 123(10):576-81. PubMed ID: 26465236
[TBL] [Abstract][Full Text] [Related]
10. TRPS1, GATA3, and SOX10 expression in triple-negative breast carcinoma.
Yoon EC; Wang G; Parkinson B; Huo L; Peng Y; Wang J; Salisbury T; Wu Y; Chen H; Albarracin CT; Resetkova E; Middleton LP; Krishnamurthy S; Gan Q; Sun H; Huang X; Shen T; Chen W; Parwani AV; Sahin AA; Li Z; Ding Q
Hum Pathol; 2022 Jul; 125():97-107. PubMed ID: 35413381
[TBL] [Abstract][Full Text] [Related]
11. Comparative expression of TRPS1, GATA3, SOX10, mammaglobin, and GCDFP-15 in effusion specimens with breast carcinoma.
Bradt A; Jing X; Smola BS; Lew M
Diagn Cytopathol; 2023 Nov; 51(11):665-673. PubMed ID: 37461248
[TBL] [Abstract][Full Text] [Related]
12. Utility of Sox10 labeling in metastatic breast carcinomas.
Nelson ER; Sharma R; Argani P; Cimino-Mathews A
Hum Pathol; 2017 Sep; 67():205-210. PubMed ID: 28843711
[TBL] [Abstract][Full Text] [Related]
13. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
Tsutsumi Y
Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
[TBL] [Abstract][Full Text] [Related]
14. A SOX10+/AR- immunoprofile may identify a subset of low positive ER carcinomas with a wider range of ER expression.
Keske A; Shetty S; Weisman P; Yu Q; McGregor SM; Xu J
Pathol Res Pract; 2023 Aug; 248():154628. PubMed ID: 37399589
[TBL] [Abstract][Full Text] [Related]
15. Metastatic triple-negative breast cancers at first relapse have fewer tumor-infiltrating lymphocytes than their matched primary breast tumors: a pilot study.
Cimino-Mathews A; Ye X; Meeker A; Argani P; Emens LA
Hum Pathol; 2013 Oct; 44(10):2055-63. PubMed ID: 23701942
[TBL] [Abstract][Full Text] [Related]
16. [Expression of SOX10 and GATA3 in breast cancer and their significance].
Liu JL; Chen DS; Cheng ZQ; Hu JT
Zhonghua Bing Li Xue Za Zhi; 2022 Jun; 51(6):536-541. PubMed ID: 35673726
[No Abstract] [Full Text] [Related]
17. The Added Value of SOX10 Immunohistochemistry to Other Breast Markers in Identifying Cytokeratin 5-Positive Triple Negative Breast Cancers as of Mammary Origin.
Sejben A; Vörös A; Golan A; Zombori T; Cserni G
Pathobiology; 2021; 88(3):228-233. PubMed ID: 33567441
[TBL] [Abstract][Full Text] [Related]
18. TRPS1 and GATA3 Expression in Invasive Breast Carcinoma With Apocrine Differentiation.
Wang J; Peng Y; Sun H; Aung PP; Resetkova E; Yam C; Sahin AA; Huo L; Ding Q
Arch Pathol Lab Med; 2024 Feb; 148(2):200-205. PubMed ID: 37074839
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological characteristics of the SOX10+ subset of HER2+ breast cancer.
Weisman P; Yu Q; Xu J
Ann Diagn Pathol; 2023 Apr; 63():152087. PubMed ID: 36669230
[TBL] [Abstract][Full Text] [Related]
20. Strong androgen receptor expression is not useful in distinguishing GATA3 + metastases.
Lionti S; La Rocca L; Nunnari CM; Barresi V
Pathol Res Pract; 2018 Dec; 214(12):2110-2114. PubMed ID: 30293951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]